Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

Liebl, Andreas; Prager, Rudolf; Binz, K.; Kaiser, Marcel; Bergenstal, Richard M.; Gallwitz, Baptist

doi:10.1111/j.1463-1326.2008.00915.x

Cited by 134 publications

(151 citation statements)

References 21 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…Although it is always necessary to exercise care when adjusting the insulin dose, and to pay attention to possible interactions with coadministered drugs, the characteristics of BIAsp 30 suggest that it may be possible to increase the dose slightly, and reduce HbA1c levels further without increasing the incidence of hypoglycemic episodes. Since several previous studies [13][14][15][16][17][18] , some of them were conducted in Japanese patients, have shown that BIAsp 30 improved HbA1c/daily glycemic profiles equally versus multiple insulin injection therapy or better than previous OAD therapy in insulinnaïve patients. Hypoglycemic episodes were not increased versus these regimens.…”

Section: Discussionmentioning

confidence: 99%

Step-up therapy with biphasic insulin aspart-70/30—Sapporo 1-2-3 study

Yoshioka¹,

Kurihara²,

Manda³

et al. 2009

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

The effectiveness of BIAsp 30 step-up therapy in achieving glycemic control in Japanese patients with type 2 diabetes mellitus was investigated. Study subjects were 99 patients with type 2 diabetes mellitus aged over 20 years who were judged to require insulin therapy due to poor glucose control (HbA1c level of ≥7.5%). BIAsp 30 dosage was determined by the patient's attending physician; co administration of hypotensive agents and antilipemic agents was permitted, but OAD co administration was limited to patients already receiving such drugs at the start of the study. Patients who did not achieve HbA1c <6.5% after 16±5 weeks with QD (Phase 1) were stepped up to BID (Phase 2). If patients still had not achieved HbA1c <6.5% after 16±5 weeks with BID, they were stepped up to TID (Phase 3). 55 of the 99 enrolled subjects completed the study and the rates of achievement of HbA1c<6.5% and HbA1c<7.0% were 45.5% and 74.5% respectively. Of all registered subjects, 5.1% (5/99) achieved HbA1c<6.5% in QD, 19.5% (16/82) in BID, and 20.6% (7/34) in TID. Statistically significant reductions in HbA1c levels were recorded at the conclusion of each phase, with no incidents requiring intervention, indicating that BIAsp 30 step-up therapy is a safe, simple therapy that can be useful in achieving better glycemic control for Japanese patients with type 2 diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 99%

Step-up therapy with biphasic insulin aspart-70/30—Sapporo 1-2-3 study

Yoshioka¹,

Kurihara²,

Manda³

et al. 2009

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…26 Basal-bolus insulin therapy was compared with biphasic premixed insulin therapy in patients who failed on oral hypoglycaemic agents or who failed on oral hypoglycaemic agents combined with basal insulin therapy. 27 There was no difference between the two regimens in terms of HbA1c reduction, fasting and postprandial glucose reduction, weight gain and hypoglycaemic events. 27 The problem is that biphasic premixed insulin therapy is not physiological and the doses of intermediate-acting insulin and short-acting insulin are not flexible.…”

Section: Insulin Strategiesmentioning

confidence: 99%

“…27 There was no difference between the two regimens in terms of HbA1c reduction, fasting and postprandial glucose reduction, weight gain and hypoglycaemic events. 27 The problem is that biphasic premixed insulin therapy is not physiological and the doses of intermediate-acting insulin and short-acting insulin are not flexible. 28 The one dose of biphasic premixed insulin cannot be adjusted without affecting the other dose.…”

Section: Insulin Strategiesmentioning

confidence: 99%

Early insulin therapy in patients with type 2 diabetes mellitus

Mashitisho

2016

Journal of Endocrinology, Metabolism and Diabetes of South Afri

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a progressive disease characterised by beta cell dysfunction and insulin resistance. Beta cell dysfunction progresses to beta cell failure. Many patients with T2DM are managed with oral agents until complications develop. 'Clinical inertia' in T2DM, defined as lack of initiation or intensification of therapy when clinically indicated, is common among clinicians. Patients are exposed to hyperglycaemia for a long time resulting in glucotoxicity to beta cells, leading to further beta cell deterioration. The traditional approach to the management of T2DM is lifestyle change, diet, exercise, weight loss, oral agents and, lastly, insulin. This traditional approach is usually carried out step-by-step and at a slow pace, with insulin offered as a last option. By the time insulin therapy is initiated, complications have already developed. It is, therefore, important for clinicians to be aware of the importance of initiating insulin therapy early to prevent poor glycaemic control and the development of diabetes-related complications.

show abstract

“…This allows us to examine the studies according to patient population: studies of insulin-naive patients initiating insulin with BIAsp 30, [35][36][37][38][39][40][41][42][43][44][45][46][47][48] and studies of patients switching existing insulin therapy to, or intensifying with, BIAsp 30.…”

Section: Type 2 Diabetesmentioning

confidence: 99%

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

Valensi

2009

DMSO

View full text Add to dashboard Cite

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

Cited by 134 publications

References 21 publications

Step-up therapy with biphasic insulin aspart-70/30—Sapporo 1-2-3 study

Step-up therapy with biphasic insulin aspart-70/30—Sapporo 1-2-3 study

Early insulin therapy in patients with type 2 diabetes mellitus

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

Contact Info

Product

Resources

About